Navigation Links
Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
Date:10/26/2007

(BRONX, NY) -- Three researchers at the Albert Einstein College of Medicine have been awarded grants from the Breast Cancer Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz and Rachel Hazan each received grants from the BCRF in its ongoing effort to support the advancement of breast cancer research. At the heart of the BCRFs generosity is its mission, which is to achieve prevention and a cure for breast cancer by providing critical funding for innovative clinical and genetic research at leading medical centers worldwide, while also increasing public awareness about good breast health.

Dr. Rohan, professor and chair of epidemiology and population health at Einstein, received $250,000 to carry out gene expression profilingusing so-called gene chipson women at risk of developing breast cancer. Using a technique that he and colleagues developed for extracting and storing RNA from breast tissue, Dr. Rohan will focus his efforts on women with benign breast disease (BDD), since women with this condition have an increased risk for breast cancer. For those BDD patients who eventually develop breast cancer, gene-expression profiles may help to predict clinical outcomes and identify those patients most likely to respond to therapy. Dr. Rohan and his colleagues have already established a multi-center cohort of more than 25,000 women who have undergone biopsies for BDD, and these breast tissue samples will be used in the study.

Dr. Horwitz, Falkenstein Professor of Cancer Research and co-chair of molecular pharmacology at Einstein, received $225,000 to study epigenetic changes (i.e., switching genes on and off in ways that dont involve changes in DNA sequence) in breast cancer cells that may help pinpoint why some breast tumors become drug-resistant. In particular, she will study whether epigenetic mechanisms cause cells to become resistant to Taxol, a drug she helped discover that has proven highly effective in treating breast cancer. Her work could lead to new drugs that reverse drug resistance and make breast tumors more sensitive to Taxol.

Dr. Hazan, associate professor of pathology at Einstein, received $225,000 to support her research effort to eradicate mestastasizing tumor cells. She will collaborate with Dr. Larry Norton of the Memorial Sloan-Kettering Cancer Center to determine the mechanism of action of the protein N-cadherin, which is produced by aggressive breast tumors and stimulates the spread of those tumors. The team will also look for potential drugs that can target this protein, with the ultimate aim of expanding the available options for treating late-stage breast cancer.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein researchers identify new way that bacteria develop resistance to antibiotics
2. Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell
3. Feinstein researchers identify intelligence gene
4. Study by Einstein researchers could lead to a novel strategy for treating obesity
5. Einstein researchers take the pulse of a gene in living cells
6. Einstein researchers demonstrate a novel approach to treating AIDS
7. Einsteins tea leaves inspire new blood separation technique
8. Researchers discover way to make cells in the eye sensitive to light
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Researchers Uncover Key Step In Manufacture of Memory Protein
11. NYU researchers simulate molecular biological clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... Feb. 3, 2017  Texas Biomedical Research Institute announced that ... Larry Schlesinger as the Institute,s new President and CEO. ... May 31, 2017. He is currently the Chair of the ... Center for Microbial Interface Biology at Ohio State University. ... new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... 2017 According to a ... (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication ... and Development, Disease-Risk) - Global Forecast to 2021" ... reach USD 53.34 Billion by 2021 from USD ... of 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics (AMA), ... maker of unmanned aircraft systems (UAS), are launching a joint program to promote ... and support educational outreach efforts. , AMA and DJI will collaborate on other ...
(Date:2/16/2017)... Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 Venture ... by a MichBio member organization. They provide an opportunity to interact with peers, make ...
(Date:2/16/2017)... 16, 2017  MDNA Life Sciences Inc. (MDNA), ... liquid biopsy tests based on the mitochondrial genome, ... license agreement with its first international commercial partner, ... test for prostate cancer, the Prostate Mitomic Test ... This is the first overseas appointment for MDNA ...
Breaking Biology Technology: